Phaseline

Companies › 3D Medicines (Sichuan)

3D Medicines (Sichuan): clinical trials, targets and expected readouts

1 active drug program in 5 registered trials: 3 Phase 2, 1 Phase 3, 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Envafolimab (KN035)
Programmed cell death 1 ligand 1 binding agent
CD274Phase 3Non-small Cell Lung Cancer; Advanced Endometrial Cancer; Solid Tumor; Solid TumorsDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05112991Envafolimab (KN035)Phase 2Advanced Endometrial CancerOncologyDec 2026
NCT05024214Envafolimab (KN035)Phase 1Solid TumorsOncologyDec 2026
NCT03667170Envafolimab (KN035)Phase 2Solid TumorOncologyDec 2026
NCT04891198Envafolimab (KN035)Phase 2Solid TumorOncologyAug 2027
NCT06123754Envafolimab (KN035)Phase 3Non-small Cell Lung CancerOncologyDec 2027

Targets

CD274 (1)

Companies with the same targets

AstraZeneca Pfizer IO Biotech ImmuneOncia Therapeutics Akeso Roche Biotheus Suzhou Suncadia Biopharmaceuticals Shine-On Biomedical Shanghai Henlius Biotech

Companies built like this

ImmuneOncia Therapeutics PharmaEssentia Protagonist Therapeutics Greenwich LifeSciences Jiangsu Healthy Life Innovation Medical Technology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.